| Old Articles: <Older 5021-5030 Newer> |
|---|
 |
Chemistry World
August 13, 2008 |
Chipscreen hits funding barrier for new drug Lu Xianping, president of Shenzhen -based pharma firm Chipscreen Biosciences, is close to seeing his dream of launching a new drug in China become reality   |
The Motley Fool
August 13, 2008
Brian Orelli |
The Good and Bad of 3SBio Chinese biotech 3SBio is still trading well below its IPO price from last year and its second-quarter earnings release isn't going to help it much. But investors willing to take a risk will likely do OK. |
The Motley Fool
August 12, 2008
Brian Lawler |
The FDA Stands Up Cardiome What does the approvable letter mean for Cardiome and other drug developers? |
Chemistry World
August 11, 2008 |
Yeast Manufacture Morphine Precursor US scientists have developed a way to produce a group of medically important plant compounds in yeast. They say their technique could be used to manufacture drugs including painkillers and new cancer treatments. |
The Motley Fool
August 8, 2008
Brian Lawler |
Flamel Tries to Get It in Gear Flamel has done a good job of reducing its cash burn, allowing it to buy some time to work on the compounds in its pipeline. |
The Motley Fool
August 8, 2008
Brian Lawler |
Not Bad, Novo Nordisk The drugmaker's performance is better than its numbers suggest. |
The Motley Fool
August 8, 2008
Rich Duprey |
Barr Hits a Home Run Barr gets to market Bayer's authorized generic version of contraceptive Yasmin without fear of competition for at least 180 days -- giving them a huge competitive edge over rivals. |
The Motley Fool
August 7, 2008
Brian Orelli |
The Next Pharma Acquisition The rate of mergers and acquisitions among drugmakers has reached a feverish pace lately, and doesn't show any signs of slowing down anytime soon. Take a look at some likely candidates. |
The Motley Fool
August 6, 2008
Brian Lawler |
BioMarin's New Drugs Mostly Hit Their Targets Near-term volatility in a drugmaker's shares can make for long-term opportunities. Such is the current case with BioMarin Pharmaceutical. |
The Motley Fool
August 6, 2008
Brian Orelli |
Onyx in the Black -- for Now Positive earnings, but losses may be ahead. Will Onyx be able to keep costs under control? |
| <Older 5021-5030 Newer> Return to current articles. |
